billS3138Event Wednesday, March 18, 2026Analyzed

Veterans SPORT Act

Bullish
Impact7/10

Summary

The Veterans SPORT Act (S.3138) mandates VA coverage of adaptive prostheses for sports, creating a new guaranteed procurement stream for prosthetic manufacturers. $ZBH is the best-positioned pure-play beneficiary with direct prosthetic product lines, while $BAX sees secondary rehabilitative equipment demand. The bill has cleared committee and awaits floor action, with $ZBH down -10.64% in 7 days, presenting a potential entry point ahead of legislative momentum.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S.3138 mandates VA coverage of adaptive sports prosthetics — creating a new, guaranteed procurement stream for prosthetic manufacturers
  • 2.$ZBH is the pure-play beneficiary with direct product lines; stock is at $81.55, down -10.64% in 7 days near 52-week lows — potential entry point
  • 3.Authorization bill but mandatory spending for VA means no separate appropriation needed for implementation
  • 4.Companion bill H.R.1971 advancing in House via voice vote increases passage probability
  • 5.$BAX sees secondary rehabilitative equipment demand, but impact is smaller and less direct than $ZBH

Market Implications

The Veterans SPORT Act introduces a new, policy-driven demand catalyst for the prosthetic device market that is entirely independent of surgical volume trends or hospital capital spending cycles. For $ZBH, trading at $81.55 after a -10.64% weekly decline, this creates a legislative catalyst that is not priced into recent declines. The stock sits near its 52-week low of $79.83, providing a downside floor against clean legislative risk. The bill's mandatory spending structure (no separate appropriation required) means the revenue stream begins upon enactment, not after a future appropriations cycle — reducing timeline risk. For $BAX at $17.67, the secondary exposure to rehabilitation equipment demand is a smaller tailwind but directionally positive. The broader market context: $ZBH's 30-day decline of -9.81% versus $BAX's 5.18% gain suggests ZBH's recent selloff is company-specific or sector rotation, making the legislative catalyst a differentiated positive signal. Investors should monitor Senate floor scheduling; with non-controversial veteran bills, leadership can bring this to a vote at any time. Passage probability is elevated given companion bill voice vote advancement and committee approval.

Full Analysis

The Veterans SPORT Act (S.3138) was reported favorably out of the Senate Committee on Veterans' Affairs on March 18, 2026. The bill amends title 38 U.S.C. §1701 to explicitly include 'adaptive prostheses and terminal devices for sports and other recreational activities' within the definition of medical services the VA must furnish. This is an authorization bill — it mandates coverage policy but does not appropriate specific funds. However, because the VA is legally obligated to provide medical services under existing appropriations, the mandatory spending nature means the VA must allocate funds from its existing medical care budget to comply once enacted. The VA's FY2026 medical care budget runs approximately $120 billion, so the incremental cost of adaptive sports prosthetics is absorbable without a separate appropriation. The bill has a companion identical bill, H.R.1971, which has been forwarded by subcommittee to full committee by voice vote — increasing passage probability. With bipartisan sponsorship (Sen. Banks, R-IN as lead) and 4 cosponsors, and given the non-controversial nature of veteran healthcare benefits, floor action is expected in the current session. $ZBH is the primary structural beneficiary: the company's prosthetic portfolio (including both upper and lower extremity devices) directly maps to the new mandated coverage. The stock has declined -10.64% over 7 days to $81.55 — near its 52-week low of $79.83 — on what appears to be broader market weakness rather than company-specific news. This creates a potential entry point ahead of legislative catalysts. $BAX is a secondary beneficiary: VA rehabilitation centers will need additional rehabilitative equipment, continuous passive motion devices, and related hospital supplies as more veterans receive and train with sports prosthetics. Baxter's 7-day decline of -2.7% to $17.67 is less pronounced, with a 30-day gain of +5.18% showing relative stability. The legislative path: Senate floor action is the next step, followed by House passage (likely given companion bill progress and voice vote), then presidential signature. No substantive opposition has emerged. Historical precedent: the VA Prosthetic and Sensory Aids Service already procures standard prosthetics; this merely expands the definition to include recreational use, a logical extension with strong bipartisan support.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$ZBH▲ Bullish
Est. $50.0M$150.0M revenue impact

What the bill does

Mandate to include adaptive prostheses and terminal devices for sports and recreational activities within VA medical services

Who must act

Department of Veterans Affairs (VA) — must furnish these devices as medical services to eligible veterans

What happens

Creates a new guaranteed procurement stream from the VA for adaptive sports prosthetics, increasing demand for specialized prosthetic product lines by an amount proportional to the eligible veteran population seeking sports-related activities

Stock impact

Zimmer Biomet has direct prosthetic product lines (including upper and lower extremity prosthetics) that qualify as adaptive prostheses; this mandate opens a new VA procurement channel separate from standard medical prosthetic demand, directly expanding revenue for this segment

$$BAX▲ Bullish
Est. $15.0M$50.0M revenue impact

What the bill does

Mandate to include adaptive prostheses within VA medical services creates secondary demand for rehabilitative equipment and supplies

Who must act

Department of Veterans Affairs (VA) and VA medical centers

What happens

Increased utilization of rehabilitation services for veterans using new adaptive prosthetics drives follow-on demand for rehabilitative equipment (continuous passive motion devices, patient monitoring, infusion systems used in post-surgical rehab) that Baxter supplies

Stock impact

Baxter's hospital products and rehabilitation equipment segments service VA hospitals; the increase in prosthetic fittings and associated rehabilitation visits will generate incremental equipment and consumable sales, though this is secondary to the primary prosthetic procurement benefit for ZBH

Market Impact Score

7/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.